BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, May 6, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
April 23, 2019
View Archived Issues
Skin microbiome study gives insights into wound healing
Read More
Why PD-1 isn't CTLA-4
Read More
Targeting FATP2 tames myeloid suppressor cells
Read More
Enanta Pharmaceuticals MAP3K5 inhibitor active in models of liver injury, metabolic disease
Read More
Zhejiang Hisun Pharmaceutical divulges new SCN9A blockers
Read More
Zonula presents CDH2 antagonists
Read More
BioAtla's conditionally active biologics show tumor-specific activity in vivo
Read More
Phase IIb data presented for CT-P27 in adults with influenza A infection
Read More
TXA-9155 potentiates antibiotics against Pseudomonas aeruginosa
Read More
Topline results from phase III study of tanezumab in osteoarthritis
Read More
FDA approves Keytruda for use with Inlyta in first-line advanced renal cell carcinoma
Read More
Forbius doses first patient with triple-negative breast cancer in phase IIa trial of AVID-100
Read More
FDA accepts IND for HER2-targeting engineered toxin body MT-5111
Read More
Fochon Pharma advances new anticancer Bcl-2, CDK4/6 inhibitors
Read More
Vaxiion to begin phase I study of VAX-014 in bladder cancer
Read More
Terns Pharmaceuticals presents preclinical data for TERN-201 in NASH models
Read More
New phase III trial in China explores combination of furaprevir and yimitasvir for chronic HCV
Read More
Phase III COAST-X study of Taltz in nonradiographic axial spondyloarthritis meets key endpoints
Read More
Vicore to develop VP-01 for diffuse systemic sclerosis
Read More
Phase I results for OP-0201 in healthy adults and adults with acute otitis media
Read More
Indalo initiates phase I study of antifibrotic drug candidate IDL-2965
Read More
